ACO

ACO Reporting Information


ACO Name and Location

  • Westchester Medical Group, P.C. (d/b/a WESTMED Medical Group)
  • Administrative Office: 2700 Westchester Avenue, Purchase, NY 10577, 914-682-0700.  

ACO Primary Contact

 

Organizational Information:

 

  • ACO participants:  WESTMED Medical Group, a multispecialty group practice is the sole participant in the ACO and all WESTMED physicians are part of the ACO.
  • ACO participants in joint ventures between ACO professional and hospitals: 
    No participants are involved in a joint venture between ACO professionals and hospitals

 

  • ACO governing body:

          1. Michael Cushner, MD, Voting Director
          2. Jenifer Johnson, MD, Voting Director
          3. Jonathan Finegold, MD, Voting Director
          4. Cordelia Schwarz, MD, Voting Director
          5. Michael Silver, MD, Voting Director, Chair
          6. Randy Stein, MD, Voting Director
          7. Ronald Dennett, MD, Voting Director
          8. Monica Rieckhoff, MD, Voting Director
          9. Joshua Waldman, MD, Voting Director
          10. Simeon Schwartz, MD, Director (ex officio)

 

  • Key ACO clinical and administrative leadership:
          1. Steven Meixler, MD
          2. Richard Morel, MD

 

  • Associated committees and committee leadership:
         1. ACO Advisory Committee:  Steven Meixler, MD and Richard Morel, MD (Co-Chair)
         2. ACO Steering Committee:   Steven Meixler, MD and Richard Morel, MD (Co-Chair)

 

  • Types of ACO participants or combination of participants that formed the ACO:
         1. ACO professionals in a group practice arrangement

Shared Savings and Losses:

 

Amount of Shared Savings/Losses

 

  • Agreement period beginning 2013, Performance Year 1:        $0.
  • Agreement period beginning 2013, Performance Year 2014:  $3,266,226.
  • Agreement period beginning 2013, Performance Year 2015:   $0.
  • Agreement period beginning 2016, Performance Year 2016:   

Shared Savings Distribution

 

Agreement period beginning 2013, Performance Year 1

  • Proportion invested in infrastructure: 0%
  • Proportion invested in redesigned care processes/resources: 0%
  • Proportion of distribution to ACO participants: 0%

 

Agreement period beginning 2013, Performance Year 2014, 2015

  • Proportion invested in infrastructure: 40%
  • Proportion invested in redesigned care processes/resources: 0%
  • Proportion of distribution to ACO participants: 60%

 

Agreement period beginning 2016, Performance Year 2016

  • Proportion invested in infrastructure:
  • Proportion invested in redesigned care processes/resources:
  • Proportion of distribution to ACO participants:

 

 

Payment Rule Waivers

  • No, our ACO does not utilize the SNF 3-Day Rule Waiver.

 

Quality Performance Results

 

2015 Reporting Period

Measure number

 

Measure Name

2015 reporting period

ACO

Mean performance

 

performance rate

rate (SSP- ACOs)

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

84.86

80.61

ACO-2

CAHPS: How Well Your Providers Communicate

94.93

92.65

ACO-3

CAHPS: Patients’ Rating of Provider

93.49

91.94

ACO-4

CAHPS: Access to Specialists

87.66

83.61

ACO-5

CAHPS: Health Promotion and Education

60.37

59.06

ACO-6

CAHPS: Shared Decision Making

70.77

75.17

ACO-7

CAHPS: Health Status/Functional Status

75.34

72.30

ACO-34

CAHPS: Stewardship of Patient Resources*

17.28

26.87

ACO-8

Risk Standardized, All Condition Readmission

13.95

14.86

ACO-35

Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)* Readmission

16.33

18.07

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes*

49.43

54.60

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure*

59.32

76.96

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

49.76

62.92

ACO-9

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

1.03

1.11

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)

0.81

1.04

ACO-11

Percent of Primary Care Physicians who Successfully Meet Meaningful Use Requirements

88.61%

80.14%

ACO-39

Documentation of Current Medications in the Medical Record*

54.32%

84.07%

ACO-13

Falls: Screening for Future Fall Risk

66.72%

56.46%

ACO-14

Preventive Care and Screening: Influenza Immunization

73.16%

62.03%

ACO-15

Pneumonia Vaccination Status for Older Adults

84.83%

63.73%

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-up

77.81%

71.15%

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

99.18%

90.16%

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

62.97%

45.25%

ACO-19

Colorectal Cancer Screening

80.65%

60.06%

ACO-20

Breast Cancer Screening

82.06%

65.67%

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

87.74%

70.04%

ACO-40

Depression Remission at Twelve Months*

N/A

N/A

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

9.98%

 

20.38%

 

ACO-41

Diabetes: Eye Exam*

81.22%

 

41.05%

 

ACO-28

Hypertension: Controlling High Blood Pressure

76.77%

 

69.62%

 

ACO-30

Ischemic Vascular Disease: Use of Aspirin or Another Antithrombotic

80.93%

 

83.82%

 

ACO-31

Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

91.43%

 

87.22%

 

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB)  Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

92.31%

 

77.73%

CAHPS =Consumer Assessment of Healthcare Providers and Systems, PQI = Prevention Quality Indicator, LVSD = left ventricular systolic dysfunction, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.

*= Measure required beginning Reporting Year 2015.

N/A= Reporting on the depression remission measure is not required for 2015, as indicated by N/A

 

 

 

 

 

 

 

 

 

 

 

2012 - 2014 Reporting Period


  2012 Performance Summary Statistics 2013 Performance Summary Statistics 2014 Performance Summary Statistics
Performance Measure ACO Performance Rate Mean Performance Rate for All ACOs ACO Performance Rate Mean Performance Rate for All ACOs ACO Performance Rate Mean Performance Rate for All ACOs
Getting Timely Care, Appointments, and Information (ACO-1) 84.55% 81.69% 83.05% 81.48% 81.87% 80.13%
How Well Your Doctors Communicate (ACO-2) 94.29% 92.84% 93.62% 92.96% 92.34% 92.39%
Patients’ Rating of Doctor (ACO-3) 92.80% 91.86% 92.93% 92.06% 92.77% 91.58%
Access to Specialists (ACO-4) 87.48% 85.11% 86.64% 85.12% 85.23% 83.97%
Health Promotion and Education (ACO-5) 61.09% 56.61% 58.06% 58.38% 56.66% 58.29%
Shared Decision Making (ACO-6) 74.98% 73.99% 72.27% 74.53% 75.44% 74.60%
Health Status/Functional Status (ACO-7) 69.94% 70.35% 72.81% 71.12% 73.44% 71.10%
Risk Standardized, All Condition Readmissions (ACO-8) 16.16% 15.42% 14.40% 14.90% 14.75% 15.15%
ASC Admissions: COPD or Asthma in Older Adults (ACO-9) 1.15% 1.13% 1.28% 1.17% .74% 1.08%
ASC Admission: Heart Failure (ACO-10) 1.04% 1.09% 1.18% 1.20% .73% 1.19%
Percent of Primary Care Providers who Qualified for EHR Incentive Payment (ACO-11) 80.00% 59.87% 63.89% 66.21% 88.89% 76.71%
Medication Reconciliation (ACO-12) 92.70% 72.37% 97.86% 73.56% 95.74% 82.61%
Falls: Screening for Fall Risk (ACO-13) 38.55% 28.27% 41.11% 39.57% 50.57% 45.60%
Influenza Immunization (ACO-14) 54.49% 50.58% 61.69% 56.93% 70.85% 57.51%
Pneumococcal Vaccination (ACO-15) 61.90% 48.62% 75.86% 54.76% 79.77% 55.03%
Adult Weight Screening and Follow-up (ACO-16) 56.46% 53.91% 79.90% 61.61% 80.10% 66.75%
Tobacco Use Assessment and Cessation Intervention (ACO-17) 95.07% 80.12% 98.05% 84.01% 99.18% 86.79%
Depression Screening (ACO-18) 46.68% 22.48% 39.85% 31.19% 48.13% 39.27%
Colorectal Cancer Screening (ACO-19) 76.80% 50.21% 77.29% 59.30% 78.33% 56.14%
Mammography Screening (ACO-20) 67.05% 62.23% 74.84% 62.05% 81.76% 61.41%
Proportion of Adults who had blood pressure screened in past 2 years (ACO-21) 0.49% 71.56% 32.06% 74.25% 34.08% 60.24%
Beneficiaries with diabetes who met of all the following criteria: Hemoglobin A1c Control (HbA1c) (< 8 percent) (ACO-22) 75.94% 64.46% 83.75% 68.58% 82.20% 25.41%
Beneficiaries with diabetes who met of all the following criteria: Low Density Lipoprotein (LDL) (< 100 mg/dL) (ACO-23) 72.53% 52.99% 73.31% 54.78% 76.04% 25.41%
Beneficiaries with diabetes who met of all the following criteria: Blood Pressure (BP) < 140/90 (ACO-24) 73.89% 66.04% 75.24% 69.53% 78.70% 25.41%
Beneficiaries with diabetes who met of all the following criteria: Tobacco Non-Use (ACO-25) 91.47% 71.72% 92.65% 63.33% 93.68% 25.41%
Beneficiaries with diabetes who met of all the following criteria: Aspirin Use (ACO-26) 90.53% 72.24% 89.02% 74.82% 89.33% 25.41%
Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent) (ACO-27) 12.97% 25.94% 7.35% 22.11% 9.82% 20.35%
Percent of beneficiaries with hypertension whose BP < 140/90 (ACO-28) 63.73% 63.22% 68.38% 67.79% 75.22% 68.02%
Percent of beneficiaries with IVD with complete lipid profile and LDL control <100mg/dl (ACO-29) 72.15% 52.02% 71.49% 55.44% 74.86% 57.29%
Percent of beneficiaries who use Aspirin or other antithrombotic (ACO-30) 80.26% 72.60% 78.61% 76.35% 81.90% 80.79%
Beta-Blocker Therapy for LVSD (ACO-31) 90.00% 79.60% 95.24% 79.82% 86.84% 82.71%
Percent of beneficiaries with CAD who met all of the following criteria: Drug Therapy for Lowering LDL-Cholesterol (ACO-32) 83.05% 69.67% 81.20% 71.60% 87.32% 66.90%
Percent of beneficiaries with CAD who met all of the following criteria: (ACE) Inhibitor or (ARB) Therapy for Patients with CAD and Diabetes and/or (LVSD) (ACO-33) 81.88% 69.71% 76.56% 69.13% 85.58% 66.90%

Note: ASC = ambulatory sensitive conditions, COPD = chronic obstructive pulmonary disease,, EHR = electronic health record, IVD = ischemic vascular disease, LVSD = left ventricular systolic dysfunction,

ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.



Page Last Modified: 10/7/2016